Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metformin, an antidiabetic drug, inhibits non-small cell lung cancer (NSCLC) cell proliferation.
• Metformin's effect on the RAS/RAF/MEK/ERK pathway is debated, with evidence for both inhibition and activation.
• Metformin-induced ERK activation can counteract its anticancer effects, necessitating combined pathway blockade.

Purpose of the Study:

• To investigate the combination therapy of metformin and trametinib in NRAS/BRAF-mutated NSCLC cells.
• To monitor signaling pathway alterations and cell viability under combination treatment.
• To determine the therapeutic potential of combined metformin and trametinib in NSCLC.

Main Methods:

• Utilized NCI-H2087 NSCLC cell line with NRAS and BRAF mutations.
• Assessed the impact of metformin and trametinib on PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling pathways.
• Monitored changes in regulatory effector proteins and cell viability.

Main Results:

• Metformin alone suppressed the PI3K/AKT/mTOR pathway and activated ERK phosphorylation.
• Combination therapy exhibited synergistic cytotoxicity at low drug doses.
• High doses of the combination therapy resulted in an antagonistic effect on cell viability.

Conclusions:

• Metformin's dual effect on PI3K/AKT/mTOR and ERK pathways influences combination therapy outcomes.
• The efficacy of metformin and trametinib combination is dependent on ERK activity modulation and cancer cell context.
• This study highlights the importance of considering ERK pathway dynamics in NSCLC treatment strategies.